Baseline clinical and laboratory descriptive features of patients by abnormality
. | Cytogenetic abnormality . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | All (n = 351) . | t(4;14)(p16;q32) (n = 42) . | t(14;16)(q32;q23) (n = 15) . | t(11;14)(q13;q32) (n = 53) . | ▵13 (n = 176) . | Del 17p13.1 (n = 37) . | |||||
| Median age, y (range) | 63 (35-84) | 59 (35-74) | 58 (41-75) | 62 (35-80) | 62 (35-82) | 64 (40-78) | |||||
| Sex, male/female, % | 62/38 | 55/45 | 47/53 | 68/32 | 57/43 | 54/46 | |||||
| ECOG PS, % | |||||||||||
| 0 to 1 | 86 | 90 | 100 | 91 | 88 | 84 | |||||
| 2 to 4 | 14 | 10 | 0 | 9 | 12 | 16 | |||||
| Plasmacytoma, % | |||||||||||
| Yes | 10 | 12 | 13 | 6 | 11 | 24 | |||||
| Lytic bone lesions, % | |||||||||||
| Yes | 61 | 62 | 54 | 62 | 60 | 70 | |||||
| Hypercalcemia, %, | |||||||||||
| Ca2+ less than 12 mg/dL | 24 | 21 | 27 | 23 | 26 | 43 | |||||
| Serum M component, % | |||||||||||
| Present, 1 or more g/dL | 83 | 90 | 73 | 72 | 78 | 78 | |||||
| Absent | 17 | 10 | 27 | 28 | 22 | 22 | |||||
| Urine M component, % | |||||||||||
| Present, detectable | 72 | 69 | 67 | 68 | 76 | 84 | |||||
| Absent | 25 | 24 | 33 | 30 | 20 | 14 | |||||
| Unknown | 3 | 7 | 0 | 2 | 5 | 3 | |||||
| Light chain type, % | |||||||||||
| κ | 63 | 48 | 40 | 60 | 59 | 54 | |||||
| λ | 33 | 50 | 60 | 34 | 36 | 46 | |||||
| Unknown | 3 | 2 | 0 | 6 | 5 | 0 | |||||
| Hemoglobin, g/dL* | 10.7 (5.1-15.8) | 9.8 (5.1-13.9) | 10.3 (7.7-13.0) | 10.5 (6.2-15.4) | 10.6 (5.1-15.5) | 10.4 (6.9-14.0) | |||||
| Peripheral blood PCs, % | 0 (0-93) | 0 (0-8) | 0 (0-12) | 0 (0-10) | 0 (0-93) | 0 (0-56) | |||||
| Bone marrow PCs, % | 43 (2-99) | 43 (4-98) | 75 (12-99) | 50 (8-86) | 42 (2-99) | 50 (11-97) | |||||
| Creatinine, mg/dL† | 1.2 (0.4-4.9) | 1.2 (0.6-4.8) | 1.1 (0.4-4.9) | 1.3 (0.5-4.7) | 1.2 (0.5-4.8) | 1.2 (0.4-4.8) | |||||
| β2-microglobulin, mg/dL‡ | 3.7 (0.6-64.0) | 3.9 (0.6-21.3) | 5.4 (1.0-64.0) | 4.0 (0.9-18.4) | 3.8 (0.6-30.3) | 4.2 (1.0-23.9) | |||||
| PCLI, % of PC | 0.4 (0-15.4) | 0.6 (0-13.2) | 1.0 (0-10) | 0.4 (0-5.9) | 0.6 (0-13.2) | 1.1 (0-10.9) | |||||
| sIL-6R, ng/mL | 187 (50-1067) | 230 (60-500) | 313 (133-733) | 156 (65-800) | 204 (50-870) | 235 (115-573) | |||||
. | Cytogenetic abnormality . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | All (n = 351) . | t(4;14)(p16;q32) (n = 42) . | t(14;16)(q32;q23) (n = 15) . | t(11;14)(q13;q32) (n = 53) . | ▵13 (n = 176) . | Del 17p13.1 (n = 37) . | |||||
| Median age, y (range) | 63 (35-84) | 59 (35-74) | 58 (41-75) | 62 (35-80) | 62 (35-82) | 64 (40-78) | |||||
| Sex, male/female, % | 62/38 | 55/45 | 47/53 | 68/32 | 57/43 | 54/46 | |||||
| ECOG PS, % | |||||||||||
| 0 to 1 | 86 | 90 | 100 | 91 | 88 | 84 | |||||
| 2 to 4 | 14 | 10 | 0 | 9 | 12 | 16 | |||||
| Plasmacytoma, % | |||||||||||
| Yes | 10 | 12 | 13 | 6 | 11 | 24 | |||||
| Lytic bone lesions, % | |||||||||||
| Yes | 61 | 62 | 54 | 62 | 60 | 70 | |||||
| Hypercalcemia, %, | |||||||||||
| Ca2+ less than 12 mg/dL | 24 | 21 | 27 | 23 | 26 | 43 | |||||
| Serum M component, % | |||||||||||
| Present, 1 or more g/dL | 83 | 90 | 73 | 72 | 78 | 78 | |||||
| Absent | 17 | 10 | 27 | 28 | 22 | 22 | |||||
| Urine M component, % | |||||||||||
| Present, detectable | 72 | 69 | 67 | 68 | 76 | 84 | |||||
| Absent | 25 | 24 | 33 | 30 | 20 | 14 | |||||
| Unknown | 3 | 7 | 0 | 2 | 5 | 3 | |||||
| Light chain type, % | |||||||||||
| κ | 63 | 48 | 40 | 60 | 59 | 54 | |||||
| λ | 33 | 50 | 60 | 34 | 36 | 46 | |||||
| Unknown | 3 | 2 | 0 | 6 | 5 | 0 | |||||
| Hemoglobin, g/dL* | 10.7 (5.1-15.8) | 9.8 (5.1-13.9) | 10.3 (7.7-13.0) | 10.5 (6.2-15.4) | 10.6 (5.1-15.5) | 10.4 (6.9-14.0) | |||||
| Peripheral blood PCs, % | 0 (0-93) | 0 (0-8) | 0 (0-12) | 0 (0-10) | 0 (0-93) | 0 (0-56) | |||||
| Bone marrow PCs, % | 43 (2-99) | 43 (4-98) | 75 (12-99) | 50 (8-86) | 42 (2-99) | 50 (11-97) | |||||
| Creatinine, mg/dL† | 1.2 (0.4-4.9) | 1.2 (0.6-4.8) | 1.1 (0.4-4.9) | 1.3 (0.5-4.7) | 1.2 (0.5-4.8) | 1.2 (0.4-4.8) | |||||
| β2-microglobulin, mg/dL‡ | 3.7 (0.6-64.0) | 3.9 (0.6-21.3) | 5.4 (1.0-64.0) | 4.0 (0.9-18.4) | 3.8 (0.6-30.3) | 4.2 (1.0-23.9) | |||||
| PCLI, % of PC | 0.4 (0-15.4) | 0.6 (0-13.2) | 1.0 (0-10) | 0.4 (0-5.9) | 0.6 (0-13.2) | 1.1 (0-10.9) | |||||
| sIL-6R, ng/mL | 187 (50-1067) | 230 (60-500) | 313 (133-733) | 156 (65-800) | 204 (50-870) | 235 (115-573) | |||||